Table 2 NS5A L31/Y93 RASs in mouse administrated with LDV/GS-558093 treatment and ASV/DCV re-treatment.

From: Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment

 

L31-Y93

L31V-Y93

L31-Y93H

L31V-Y93H

week 0

95.9%

—

—

—

week 10 (A)

3.0%

4.0%

90.1%

0.9%

(LDV/GS-558093 post 6 w)

week 14 (B)

—

—

99.4% *

—

(LDV/GS-558093 post 10 w)

week 26 (C)

—

—

0.7%

98.6%

(ASV/DCV post 8 w)

week 29

—

—

17.4%

75.4%

(ASV/DCV post 11 w)

week 31

—

—

9.0%

82.9%

(ASV/DCV post 13 w)

  1. *Represents the putative original variants before treatment that contributed to the L31M/V-Y93H double substitution after treatment.
Back to article page